필리핀 - 영어 - FDA (Food And Drug Administration)

under authority by: pfizer, inc.- new york, ny, usa; importer: pfizer, inc. - methylprednisolone - tablet - 4mg

사우디아라비아 - 영어 - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

pfizer, italy - methylprednisolone - tablet - 4 mg

사우디아라비아 - 영어 - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

pfizer, italy - methylprednisolone - tablet - 4 mg

일본 - 영어 - すりの適正使用協議会 RAD-AR Council, Japan

pfizer pharmaceuticals inc. - methylprednisolone - pink tablet with split line, major axis: 8.2 mm, minor axis: 5.6 mm, thickness: 2.3 mm

방글라데시 - 영어 - DGDA (Directorate General of Drug Administration)

opsonin pharma limited - mebhydrolin - tablet - 50 mg

벨기에 - 영어 - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

pfizer sa-nv - methylprednisolone 4 mg - tablet - methylprednisolone

나미비아 - 영어 - Namibia Medicines Regulatory Council

pfizer laboratories (pty) ltd - methylprednisolone - tablet - each tablet contains methylprednisolone 16,0 mg

나미비아 - 영어 - Namibia Medicines Regulatory Council

pfizer laboratories (pty) ltd - methylprednisolone - tablet - each tablet contains methylprednisolone 4 mg

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - methylprednisolone sodium succinate, quantity: 663.13 mg (equivalent: methylprednisolone, qty 500 mg) - injection, powder for - excipient ingredients: monobasic sodium phosphate monohydrate; dibasic sodium phosphate; sodium hydroxide - when oral therapy is not feasible and the strength, dosage form and route of administration of the drug reasonably lend the preparation to the treatment of the condition, solu-medrol powder for injection is indicated only for intravenous or intramuscular use in the following conditions:,endocrine disorders,? primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogues may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance).,? acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogues are used).,? preoperatively and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful.,? shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected.,? c

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - methylprednisolone sodium succinate, quantity: 1.326 g (equivalent: methylprednisolone, qty 1 g) - injection, powder for - excipient ingredients: monobasic sodium phosphate monohydrate; dibasic sodium phosphate; sodium hydroxide - when oral therapy is not feasible and the strength, dosage form and route of administration of the drug reasonably lend the preparation to the treatment of the condition, solu-medrol powder for injection is indicated only for intravenous or intramuscular use in the following conditions:,endocrine disorders,? primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogues may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance).,? acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogues are used).,? preoperatively and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful.,? shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected.,? c